LP
NVAX icon

LMR Partners’s Novavax NVAX Stock Holding History

LMR Partners’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31,613
Closed -$254K – 1564
2024
Q4 		$254K Hold
31,613
– – ﹤0.01% 927
2024
Q3 		$399K Buy
+31,613
New +$408K ﹤0.01% 871
2022
Q4 		– Sell
-250,636
Closed -$4.56M – 1219
2022
Q3 		$4.56M Buy
250,636
+17,943
+8% +$778K 0.08% 297
2022
Q2 		$12M Buy
232,693
+210,778
+962% +$10.9M 0.2% 109
2022
Q1 		$1.61M Sell
21,915
-210,168
-91% -$18.7M 0.02% 632
2021
Q4 		$33.2M Buy
+232,083
New +$39.9M 0.34% 46
2021
Q2 		– Sell
-17,695
Closed -$3.21M – 1264
2021
Q1 		$3.21M Sell
17,695
-5,901
-25% -$1.18M 0.08% 225
2020
Q4 		$2.63M Buy
+23,596
New +$2.51M 0.04% 168

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LMR Partners's NVAX Position: Q1 2025 in Review

LMR Partners sold out of Novavax (NVAX) in Q1 2025, closing a stake of 31,613 shares — an estimated $254K sold.

LMR Partners first reported a position in NVAX in Q4 2020 and held it in 8 quarters. The position peaked at $33.2M in Q4 2021. 245 funds tracked by Wall St. Rank hold NVAX as of Q1 2025.

  • LMR Partners reported no remaining Novavax position as of Q1 2025 after selling out during the quarter.
  • LMR Partners sold 31,613 Novavax shares in Q1 2025, an estimated $254K.
  • LMR Partners first reported a position in Novavax in Q4 2020 and held it in 8 quarters.
  • LMR Partners's Novavax position peaked at $33.2M in Q4 2021.
  • 245 funds tracked by Wall St. Rank held Novavax as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.